Topical glutamine therapy in experimental inflammatory bowel disease

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) poses a significant health challenge.
• Current treatments for colitis have limitations and side effects.
• Investigating novel therapeutic agents for colitis is crucial.

Purpose of the Study:

• To evaluate the efficacy of L-glutamine and prednisolone enemas in an experimental model of colitis.
• To compare the anti-inflammatory effects of L-glutamine versus prednisolone.
• To assess the impact of these treatments on systemic inflammatory markers and overall animal health.

Main Methods:

• Colitis was induced in Wistar rats using trinitrobenzenesulphonic acid (TNBS) in ethanol.
• Animals received enemas of prednisolone, L-glutamine, or placebo twice daily.
• Disease activity was assessed via colon macroscopic score (CMS), colon weight, body weight gain, food intake, thymic and splenic weights, and plasma levels of IL-6 and alpha(2)-macroglobulin.

Main Results:

• TNBS-induced colitis significantly increased CMS, colon weight, splenic weight, IL-6, and alpha(2)-macroglobulin, while decreasing body weight gain, food intake, and thymic weight.
• Prednisolone enemas significantly reduced colonic inflammation, improved body weight gain, food intake, and thymic weight, and lowered plasma IL-6.
• L-glutamine enemas failed to improve colitis markers and were associated with an exaggerated alpha(2)-macroglobulin response.

Conclusions:

• Prednisolone enemas demonstrate therapeutic potential in managing experimental colitis.
• L-glutamine enemas were ineffective and potentially detrimental in this model.
• Further research into steroid-based therapies for colitis is warranted, while glutamine's role requires re-evaluation.